Orchestra BioMed Holdings (OBIO) Gross Profit (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Gross Profit of $78000.0 for Q1 2026, down 90.53% year-over-year from $824000.0 in Q1 2025, and down 99.75% quarter-over-quarter from $30.9 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Gross Profit (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Gross Profit for 5 consecutive years, with $78000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Profit fell 90.53% year-over-year to $78000.0; the TTM figure through Mar 2026 stood at $32.5 million (up 1118.04% YoY), while the FY2025 annual figure was $33.3 million, up 1267.79% from the prior year.
- Gross Profit fell to $78000.0 in Q1 2026 per OBIO's latest filing, from $30.9 million in the prior quarter.
- Across five years, Gross Profit topped out at $30.9 million in Q4 2025 and bottomed at $78000.0 in Q1 2026.
- Historically, Gross Profit has averaged $2.5 million across 5 years, with a median of $812000.0 in 2025.
- Annual changes were most pronounced in 2025 — Gross Profit soared 15728.72% — and 2026, when it plunged 90.53%.
- Orchestra BioMed Holdings' Gross Profit stood at $1.0 million in 2022, then slumped by 79.52% to $215000.0 in 2023, then retreated by 9.3% to $195000.0 in 2024, then jumped by 15728.72% to $30.9 million in 2025, then plunged by 99.75% to $78000.0 in 2026.
- Business Quant data shows OBIO's Gross Profit at $78000.0 in Q1 2026, $30.9 million in Q4 2025, and $812000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63,000.00 |
| Jun 30, 2026 | 63,000.00 |
| Mar 31, 2026 | 78,000.00 |
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 30.87 Mn |
| Dec 31, 2025 | 30.87 Mn |
| Sep 30, 2025 | 812,000.00 |
| Sep 30, 2025 | 812,000.00 |
| Jun 30, 2025 | 790,000.00 |
| Jun 30, 2025 | 790,000.00 |
| Mar 31, 2025 | 824,000.00 |
| Mar 31, 2025 | 824,000.00 |
| Dec 31, 2024 | 195,000.00 |
| Dec 31, 2024 | 195,000.00 |
| Sep 30, 2024 | 919,000.00 |
| Sep 30, 2024 | 919,000.00 |
| Jun 30, 2024 | 734,000.00 |
| Jun 30, 2024 | 734,000.00 |
| Mar 31, 2024 | 586,000.00 |
| Mar 31, 2024 | 586,000.00 |